1. Scrip
  2. >>Business

GSK Gets A Lucky Q1 Boost, But All Eyes Are On RSV Vaccine Readout

Revenues Up By 32%

 
• By Andrew McConaghie

GlaxoSmithKline has just acquired a late-stage oncology asset, and sales of Shingrix are on the up again, but the outcome of its RSV vaccine study remains the main focus for 2022.

GSK Skyline
GlaxoSmithKline will spin out its consumer health division in July - by which time its RSV vaccine results should also be ready. • Source: Alamy

GlaxoSmithKline has enjoyed a strong start to the year with thanks to a rebound in orders for shingles vaccine Shingrix, big revenues for its COVID-19 antibody therapy Xevudy and strong consumer division growth, among other drivers.

Its first-quarter revenues beat expectations, rising by 32% to £9.78bn ($12.27bn). However, many of the contributing factors were one-offs – including a £924m patent settlement from Gilead Sciences, Inc

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Business

More from Scrip